Topical tacrolimus;Le médicament du mois. Le tacrolimus topique (Protopic®)

Revue Medicale de Liege

Volumn 57, Issue 8, 2002, Pages 552-555

  Pierard G E ^a   Pierard Franchimont C ^a   Paquet, P ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atopic dermatitis; Immunomodulator; Macrolactam

Indexed keywords

IMMUNOMODULATING AGENT; TACROLIMUS;

ATOPIC DERMATITIS; CYTOKINE RELEASE; DRUG EFFICACY; HERPES; HUMAN; IMMUNOMODULATION; INFECTION RISK; IRRITANT DERMATITIS; RISK ASSESSMENT; SHORT SURVEY;

ADMINISTRATION, CUTANEOUS; DERMATITIS, ATOPIC; DRUG TOLERANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RISK FACTORS; SKIN ABSORPTION; TACROLIMUS; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME;

EID: 0036379383     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (37)

1. Ruzicka T, Assmann T, Homey B. - Tacrolimus: the drug for the turn of the millennium? Arch Dermatol, 1999, 135, 574-580.
2. Borhövd E, Burgdorf WH, Wollenberg A. - Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol, 2001, 45, 736-743.
3. Homey B, Assmann T, Vohr HW, et al. - Topical FK506 supresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol, 1998, 160, 5331-5340.
4. Wesselborg S, Fruman DA, Sagoo JK, et al. - Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem, 1996, 271, 1274-1277.
5. Schneider G, Heinfling A, Klein HS, et al. - The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promotor. Immunobiology, 1995, 193, 268-272.
6. Michel G, Ried C, Beetz A. - FK-506 blocks expression of interleukin-8 receptor in normal human keratinocytes. J Invest Dermatol, 1993, 100, 449.
7. Wollenberg A, Kraft S, Hanau D, et al. - Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol, 1996, 106, 446-453.
8. Panhans-Gross A, Novak N, Kraft S, et al. - Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol, 2001, 107, 345-352.
9. Wollenberg A, Sharma S, von Bubnoff D, et al. - Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol, 2001, 107, 519-525.
10. De Paulis A, Stellato C, Cirillo R, et al. - Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol, 1992, 99, 723-728.
11. The European FK506 Multicentre Psoriasis Study Group. - Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double blind, placebo-controlled study. Arch Dermatol, 1996, 132, 419-423.
12. Willemaers V, Stas I, Piérard-Franchimont C, et al. - La dermatite atopique. Rev Med Liège, 1998, 53, 67-70.
13. Piérard GE, Piérard-Franchimont C. - Des herbes pour la dermatite atopique: phytothérapie de l'apprenti sorcier ou mascarade trompeuse et coupable? Rev Med Liège, 1999, 54, 539-540.
14. Aoyama H, Tabata N, Tanaka M, et al. - Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK-506 ointment. Br J Dermatol, 1995, 133, 494-496.
15. Ruzicka T, Bieber T, Schöpf E, et al. - A short term trial of tacrolimus ointment for atopic dermatis. N Engl J Med, 1997, 337, 816-821.
16. Marone G. - Tacrolimus ointment for atopic dermatitis. N Engl J Med, 1998, 393, 1788.
17. Fleischer AB Jr. - Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Aller Clin Immunol, 1999, 104, S126-S130.
18. Assmann T, Homey B, Ruzicka T. - Topical tacrolimus for the treatment of inflammatory skin diseases. Exp Opin Pharmacother, 2001, 2, 1167-1175.
19. Cheer SM, Plosker GL. - Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol, 2001, 2, 389-406.
20. Gianni LM, Sulli MM. - Topical tacrolimus in the treatment of atopic dermatitis. Ann Pharmacother, 2001, 35, 943-946.
21. Kawakami T, Soma Y, Morita E, et al. - Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology, 2001, 203, 32-37.
22. Nghiem P. - "Topical immunomodulators?" introducing old friends and a new ally, tacrolimus. J Am Acad Dermatol, 2001, 44, 111-113.
23. Paller A, Eichenfield L, Leung D, et al. - A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol, 2001, 44 (suppl 1), S47-S57.
24. Skaehill PA. - Tacrolimus in dermatologic disorders. Ann Pharmacother, 2001, 35, 582-588.
25. Soter N, Fleischer A, Webster G, et al. - Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. II. Safety. J Am Acad Dermatol, 2001, 44 (suppl 1), S39-S46.
26. Sugiura H, Uehara M, Hoshino N, et al. - An open study of a lotion formulation to improve tolerance of tacrolimus in facial atopic dermatitis. Br J Dermatol, 2001, 145, 795-798.
27. Lacour JP. - Tacrolimus topique en dermatologie: que peut-on en attendre? Ann Dermatol Venereol, 2001, 128, 1291-1294.
28. Lübbe J. - Topical tacrolimus for atopic dermatitis: euphoria and vigilance. Dermatology, 2001, 203, 1-2.
29. Kang S, Lucky AW, Pariser D, et al. - Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol, 2001, 44, S58-S64.
30. Reitamo S, Rissanen J, Remitz A, et al. - Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol, 1998, 111, 396-398.
31. Letawe C, Piérard-Franchimont C, Piérard GE. - Squamometry in rating the efficacy of topical corticosteroids in atopic dermatitis. Eur J Clin Pharmacol, 1996, 51, 253-258.
32. Lauerma AI, Surber C, Maibach HI. - Absorption topical tacrolimus (FK-506) in vitro through human skin comparison with Cyclosporin A. Skin Pharmacol, 1997, 10 (5-6), 230-234.
33. Kawashima M, Nakagawa H, Ohtsuki M, et al. - Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet, 1996, 348, 1240-1241.
34. Petit L, Braham C, Nikkels C, et al. - Comment je traite .... un herpés labial récurrent. Rev Med Liége, 2002, 57, 67-71.
35. Reitamo S, Wollenberg A, Schöpf E, et al. - Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol, 2000, 136, 999-1006.
36. Lubbe J, Pournaras CC, Saurat JH. - Eczma herpeticum during treatment of atopic dermatitis with 0.1 tacrolimus ointment. Dermatology, 2000, 201, 249-251.
37. Drake L, Prendergast M, Maher R, et al. - The impact of tacrolimus ointment of health-related quality of life of adult and pediatric patient with atopic dermatitis. J Am Acad Dermatol, 2001, 44, S65-72.